| Yerushalmi, Rinat |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 400 | Europe, US, RoW | Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio | Stemline Therapeutics, Inc. | Breast Cancer, Metastatic Breast Cancer | 12/24 | 08/26 | | |
| Westrup, Jennifer |
| Recruiting | 3 | 220 | Europe, Canada, US, RoW | Selinexor, KPT-330, Matching Placebo for selinexor | Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group | Endometrial Cancer | 01/25 | 01/28 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Nagarkar, Rajnish |
NCT04707196: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer |
|
|
| Completed | 4 | 200 | RoW | Abemaciclib, LY2835219, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant | Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 01/23 | 01/23 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma |
|
|
| Recruiting | 3 | 270 | RoW | BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo | Biocad | Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced | 04/24 | 04/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy | Nanobiotix, Nanobiotix SA | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients |
|
|
| Active, not recruiting | 2 | 170 | US, RoW | OQL011, Vehicle Ointment | OnQuality Pharmaceuticals (USA) LLC | Hand-Foot Skin Reaction (HFSR) | 02/24 | 06/24 | | |
| vural, meltem |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
NCT05410704: Effects of Pelvic Floor Muscle Training and Diaphragmatic Breathing Exercise on Body Posture |
|
|
| Recruiting | N/A | 36 | RoW | exercises | Saglik Bilimleri Universitesi | Telerehabilitation, Body Posture, Pelvic Floor Muscle Training, Diaphragmatic Breathing, Quality of Life | 05/22 | 05/22 | | |
| Recruiting | N/A | 300 | RoW | | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Covid19 | 04/21 | 05/21 | | |
NCT05509556: Talocalcaneal Angle in Calcaneal Spur Formation |
|
|
| Recruiting | N/A | 150 | RoW | talocalcaneal angle measurement | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Foot Callus, Plantar Fascitis | 08/22 | 11/22 | | |
| Sonnenblick, Amir |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles |
|
|
| Recruiting | N/A | 30000 | Europe, Canada, US, RoW | MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint | Agendia | Breast Cancer | 04/37 | 12/37 | | |
| Breuer, Shani |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Hacibekiroglu, Ilhan |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | N/A | 6000 | RoW | | Mahmut Gumus | Non Small Cell Lung Cancer, Small-cell Lung Cancer | 12/24 | 02/25 | | |
| KARAAHMETOÄžLU, Fulya Senem |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
NCT05855447: Muscles Oxygenation During Exercise in Fibrosing Interstitial Lung Diseases |
|
|
| Completed | N/A | 36 | RoW | NIRS device usage during 6MWT, Peripheral Muscle Strength Measurement, Pulmonary Function Test | Saglik Bilimleri Universitesi | Lung Diseases, Interstitial, Exercise, Compulsive, Oxygen Deficiency | 10/23 | 10/23 | | |
NCT06303479: The Effect of Telerehabilitation-Based Respiratory Exercise Programs on Lung Capacity |
|
|
| Not yet recruiting | N/A | 26 | RoW | Non-Instrumental breathing exercise group, Instrumental breathing exercise group | Saglik Bilimleri Universitesi | Breathing Exercises, Telerehabilitation | 05/24 | 09/24 | | |
NCT05738720: Effect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD |
|
|
| Recruiting | N/A | 24 | RoW | Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer), Exercise Programme | Saglik Bilimleri Universitesi | COPD Exacerbation | 12/24 | 12/24 | | |
| ÖZCAN, Zeynep Betül |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
NCT05855447: Muscles Oxygenation During Exercise in Fibrosing Interstitial Lung Diseases |
|
|
| Completed | N/A | 36 | RoW | NIRS device usage during 6MWT, Peripheral Muscle Strength Measurement, Pulmonary Function Test | Saglik Bilimleri Universitesi | Lung Diseases, Interstitial, Exercise, Compulsive, Oxygen Deficiency | 10/23 | 10/23 | | |
NCT05738720: Effect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD |
|
|
| Recruiting | N/A | 24 | RoW | Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer), Exercise Programme | Saglik Bilimleri Universitesi | COPD Exacerbation | 12/24 | 12/24 | | |
| Kulac, Vildan |
| Completed | N/A | 81 | RoW | warm shower | Sakarya University | Labor Pain, Parenting, Childbirth Problems | 03/23 | 07/23 | | |
| Baskaya, Yasemin Hamlacı |
| Completed | N/A | 81 | RoW | warm shower | Sakarya University | Labor Pain, Parenting, Childbirth Problems | 03/23 | 07/23 | | |
| Completed | N/A | 80 | RoW | music therapy | Sakarya University | Sleep Quality, Premature Labor, Risk-Taking | 11/23 | 05/24 | | |
NCT06711198: Virtual Reality Simulation in Episiotomy Training |
|
|
| Completed | N/A | 95 | RoW | virtual reality simulation | Sakarya University | Episiotomy, Virtual Simulation | 01/25 | 01/25 | | |
| ÜSTÜN, Işıl |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
| KURAL, Alev |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
| KURAŞ, Sibel |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
| ERDOĞAN, Bekir |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
| PENÇE, Halime Hanım |
| Completed | N/A | 30 | RoW | Exercise Programme, Experiments | Saglik Bilimleri Universitesi | Osteoarthritis, Knee, Epigenetic Disorder, Quality of Life, Depression, Pain | 09/19 | 06/20 | | |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
| ÇIRACI, Mehmet Zahid |
| Completed | N/A | 60 | RoW | exercise, gene expressions of miRNA | Saglik Bilimleri Universitesi | Rheumatoid Arthritis | 09/19 | 06/20 | | |
